Jim Wu, M.D., MBA, Founder of SaniMed Science Group and Chairman of BioTech (Shanghai), has joined the U.S.-based Bullpen Club as a Lifetime Founder Member and Money Ball Program Coach. Leveraging nearly 30 years of experience in biotech, MedTech, AI healthcare, and cross-border investment, he will help connect Chinese and Asian healthcare innovators with global capital, strategic partners, and international acceleration platforms to advance global commercialization and colla

At the 2025 U.S.–China Forum on Health Innovation and Collaboration in Shanghai, Rochester Mayor Kim Norton presented DMC’s US $6 billion health-innovation project, while BioTech (Shanghai) and SaniMed Science Group led discussions on AI, FDA readiness, and global expansion—strengthening U.S.–China partnerships and empowering Chinese MedTech firms to enter the U.S. market.

BioTech (Shanghai) Chairman Jim Wu attended the 2025 Heartland Connect for Trade & Investment Conference, hosted by USHCA, engaging leaders from Mayo Clinic’s DMC and U.S. healthcare organizations. The event fostered dialogue on AI, healthcare access, and innovation, advancing U.S.–China collaboration and helping Chinese MedTech firms enter the American market.

SaniMed Science Group (USA) has partnered with Gary Carruthers, former Medtronic executive and GI technology expert, as Market Advisor to guide Asian—especially Chinese—MedTech firms in R&D, FDA approval, and market entry. Together with BioTech (Shanghai), SaniMed is building a dual-platform to help Chinese innovators truly enter the U.S. healthcare market.

On June 3, 2025, SaniMed Founder Jim Wu attended the “Build a Biotech” Forum hosted by JLABS in Houston. The event focused on turning biotech innovations into sustainable businesses. With leaders from JJDC and the global biotech ecosystem, the forum explored strategies for funding, IP, and commercialization. SaniMed continues to foster global collaboration in life sciences innovation.